Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)	$ (12,756,958)	$ (2,080,958)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued by licensee to subsidiary in payment of services	$ (192,000)
Stock issued for services rendered by consultants		$ 26,180
Stock issued for interest		3,570
Stock issued for expenses		$ 48,000
Interest Expense attributable to amortization of discount	$ 150,806
Additional paid in Capital	1,010,650	$ 300,000
Loss on Settlement of Debt through Equity Issuance	10,133,872	$ 1,112,230
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses	(10,000)
Increase (Decrease) in Accounts Payable	9,484	$ 19,920
Increase (Decrease) in Accrued Expenses	207,624	12,397
Increase (Decrease) in bank Overdraft	(6,137)	6,137
(Increase) Decrease in Interest Receivable	$ (1,148)	(233)
Increase (Decrease) in Due to Affiliate		(34,895)
(Increase) Decrease in Note Receivable	$ (1,629)	(10,422)
Net Cash Provided by (Used in) Operating Activities	$ (1,455,436)	(598,074)
CASH FLOWS FROM FINANCING ACTIVITIES
Preferred Stock issued for Cash		$ 100,000
Stock in subsidiary sold for cash	$ 50,000
Principal borrowings (repayments) on notes and Convertible Debentures	206,603	$ 316,862
Principal borrowings (repayments) on Convertible Debentures	$ 1,272,686
(Increase) Decrease in Deferred Financing Costs		$ 65,000
Net Cash Provided by (Used in) Financing Activities	$ 1,531,289	481,862
Net Increase (Decrease) in Cash	75,853	(116,212)
Cash at Beginning of Period	502	116,714
Cash at End of Period	76,355	502
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	157,500	$ 158,000
Common Shares of Regen Biopharma, Inc. Issued for Debt	1,002,686
Cash paid for Interest	0	$ 0
Cash paid for Income tax	$ 0	$ 0